Infant Bacterial Therapeutics AB OMXSTO:IBT_B:
Q3 NET SALES SEK 0 THOUSAND
Q3 OPERATING PROFIT SEK -48,457 THOUSAND
Infant Bacterial Therapeutics Q3 Operating Loss SEK 48.5 Mln
Earlier from Infant Bacterial Therapeutics Ab Class B
- Infant Bacterial Therapeutics AB: Quarterly Trading Report 2025 Q3
- IBT_B: FDA review of IBP-9414 progresses as losses narrow and launch preparations intensify